Suppr超能文献

颗粒蛋白前体与氨基己糖苷酶 A 结合,改善泰萨二氏症 GM2 神经节苷脂蓄积和溶酶体贮积。

Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.

机构信息

Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York, NY, 10003, USA.

Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, 610041, China.

出版信息

J Mol Med (Berl). 2018 Dec;96(12):1359-1373. doi: 10.1007/s00109-018-1703-0. Epub 2018 Oct 20.

Abstract

Tay-Sachs disease (TSD) is a lethal lysosomal storage disease (LSD) caused by mutations in the HexA gene, which can lead to deficiency of β-hexosaminidase A (HexA) activity and consequent accumulation of its substrate, GM2 ganglioside. Recent reports that progranulin (PGRN) functions as a chaperone of lysosomal enzymes and its deficiency is associated with LSDs, including Gaucher disease and neuronal ceroid lipofuscinosis, prompted us to screen the effects of recombinant PGRN on lysosomal storage in fibroblasts from 11 patients affected by various LSDs, which led to the isolation of TSD in which PGRN demonstrated the best effects in reducing lysosomal storage. Subsequent in vivo studies revealed significant GM2 accumulation and the existence of typical TSD cells containing zebra bodies in both aged and ovalbumin-challenged adult PGRN-deficient mice. In addition, HexA, but not HexB, was aggregated in PGRN-deficient cells. Furthermore, recombinant PGRN significantly reduced GM2 accumulation and lysosomal storage in these animal models. Mechanistic studies indicated that PGRN bound to HexA through granulins G and E domain and increased the enzymatic activity and lysosomal delivery of HexA. More importantly, Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively bound to HexA and reduced the GM2 accumulation. Collectively, these studies not only provide new insights into the pathogenesis of TSD but may also have implications for developing PGRN-based therapy for this life-threatening disorder. KEY MESSAGES: GM2 accumulation and the existence of typical TSD cells containing zebra bodies are detected in both aged and ovalbumin-challenged adult PGRN deficient mice. Recombinant PGRN significantly reduces GM2 accumulation and lysosomal storage both in vivo and in vitro, which works through increasing the expression and lysosomal delivery of HexA. Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively binds to to HexA and reduces GM2 accumulation.

摘要

泰萨二氏症(Tay-Sachs disease,TSD)是一种致命的溶酶体贮积病(lysosomal storage disease,LSD),由 HexA 基因突变引起,可导致β-己糖胺酶 A(HexA)活性缺乏,进而其底物 GM2 神经节苷脂蓄积。最近有报道称颗粒体蛋白(progranulin,PGRN)作为溶酶体酶的伴侣,其缺乏与包括戈谢病(Gaucher disease)和神经元蜡样脂褐质沉积症(neuronal ceroid lipofuscinosis)在内的 LSD 相关,这促使我们筛选重组 PGRN 对各种 LSD 患者成纤维细胞溶酶体贮积的影响,由此分离出 PGRN 对减轻溶酶体贮积效果最好的 TSD。随后的体内研究显示,在老年和卵清蛋白(ovalbumin)挑战的 PGRN 缺陷型成年小鼠中,GM2 蓄积明显,并存在具有斑马体的典型 TSD 细胞。此外,PGRN 缺陷型细胞中仅 HexA 发生聚集,而非 HexB。此外,重组 PGRN 可显著减少这些动物模型中的 GM2 蓄积和溶酶体贮积。机制研究表明,PGRN 通过颗粒体蛋白 G 和 E 结构域与 HexA 结合,并增加 HexA 的酶活性和溶酶体转运。更为重要的是,携带颗粒体蛋白 E 结构域的工程化 PGRN 衍生物 Pcgin 也能有效结合 HexA,并减少 GM2 蓄积。总之,这些研究不仅为 TSD 的发病机制提供了新的见解,也可能为开发基于 PGRN 的这种危及生命的疾病的治疗方法提供了依据。

关键信息

在老年和卵清蛋白挑战的 PGRN 缺陷型成年小鼠中,均检测到 GM2 蓄积和具有斑马体的典型 TSD 细胞的存在。重组 PGRN 可显著减少体内和体外 GM2 蓄积和溶酶体贮积,其作用机制是通过增加 HexA 的表达和溶酶体转运。携带颗粒体蛋白 E 结构域的工程化 PGRN 衍生物 Pcgin 也能有效结合 HexA 并减少 GM2 蓄积。

相似文献

1
Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.
J Mol Med (Berl). 2018 Dec;96(12):1359-1373. doi: 10.1007/s00109-018-1703-0. Epub 2018 Oct 20.
3
Autophagic flux is impaired in the brain tissue of Tay-Sachs disease mouse model.
PLoS One. 2023 Mar 16;18(3):e0280650. doi: 10.1371/journal.pone.0280650. eCollection 2023.
4
A pathogenic HEXA missense variant in wild boars with Tay-Sachs disease.
Mol Genet Metab. 2021 Jul;133(3):297-306. doi: 10.1016/j.ymgme.2021.05.001. Epub 2021 May 7.
5
Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease.
Orphanet J Rare Dis. 2018 Sep 17;13(1):152. doi: 10.1186/s13023-018-0886-3.
7
Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
Biochem Biophys Rep. 2016 Jun 8;7:157-163. doi: 10.1016/j.bbrep.2016.04.012. eCollection 2016 Sep.
9
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
Exp Neurol. 2018 Jan;299(Pt A):26-41. doi: 10.1016/j.expneurol.2017.09.012. Epub 2017 Sep 30.

引用本文的文献

1
The role of endolysosomal progranulin and TMEM106B in neurodegenerative diseases.
Mol Neurodegener. 2025 Jul 26;20(1):86. doi: 10.1186/s13024-025-00873-6.
3
TFEB overexpression alleviates autophagy-lysosomal deficits caused by progranulin insufficiency.
Sci Rep. 2025 Jul 19;15(1):26217. doi: 10.1038/s41598-025-12268-0.
4
Reduction of sphingomyelinase activity associated with progranulin deficiency and frontotemporal dementia.
Neurobiol Dis. 2025 Sep;213:107024. doi: 10.1016/j.nbd.2025.107024. Epub 2025 Jul 7.
5
PGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases.
Commun Biol. 2025 Jun 2;8(1):844. doi: 10.1038/s42003-025-08272-9.
6
Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.
Hum Mol Genet. 2024 Oct 7;33(20):1771-1788. doi: 10.1093/hmg/ddae113.
8
Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease.
J Neuroinflammation. 2023 Nov 30;20(1):286. doi: 10.1186/s12974-023-02965-w.
9
Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances.
Cytokine Growth Factor Rev. 2024 Apr;76:142-159. doi: 10.1016/j.cytogfr.2023.11.001. Epub 2023 Nov 11.
10
IRE1α protects against osteoarthritis by regulating progranulin-dependent XBP1 splicing and collagen homeostasis.
Exp Mol Med. 2023 Nov;55(11):2376-2389. doi: 10.1038/s12276-023-01106-w. Epub 2023 Nov 1.

本文引用的文献

2
Progranulin acts as a shared chaperone and regulates multiple lysosomal enzymes.
Genes Dis. 2017 Sep;4(3):125-126. doi: 10.1016/j.gendis.2017.05.001. Epub 2017 Jun 23.
3
Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency.
Cell Rep. 2017 Sep 12;20(11):2565-2574. doi: 10.1016/j.celrep.2017.08.056.
5
Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo.
Hum Mol Genet. 2017 Aug 1;26(15):2850-2863. doi: 10.1093/hmg/ddx162.
6
Foxo4- and Stat3-dependent IL-10 production by progranulin in regulatory T cells restrains inflammatory arthritis.
FASEB J. 2017 Apr;31(4):1354-1367. doi: 10.1096/fj.201601134R. Epub 2016 Dec 23.
7
Progranulin as a Novel Factor in Gaucher Disease.
EBioMedicine. 2016 Nov;13:13-14. doi: 10.1016/j.ebiom.2016.11.006. Epub 2016 Nov 5.
8
Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study.
Clin Rheumatol. 2017 Mar;36(3):507-516. doi: 10.1007/s10067-016-3467-7. Epub 2016 Nov 9.
9
Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.
EBioMedicine. 2016 Nov;13:212-224. doi: 10.1016/j.ebiom.2016.10.010. Epub 2016 Oct 24.
10
Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation.
Mol Biol Cell. 2016 Dec 1;27(24):3813-3827. doi: 10.1091/mbc.E16-01-0012. Epub 2016 Sep 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验